The Pune based pharmaceutical company, Twilight Litaka Pharma Ltd (TLPL), is expanding its domestic operations with the initial investment of Rs 8 crore. The company is having four marketing divisions across India and it is in the process setting up another five marketing divisions for antibiotic segment. All the new divisions will be operational by the end current financial year.

Speaking with Pharmabiz, Pankaj, K Undwar, general manager, said, "We are expanding our business portfolio through organic routes. We have plans to set up five more marketing division across India. Till now we haven't decided the location but that will be decided in another two months. New divisions will begin operation by the end of current financial year. Overall, we have plans to employ 300 field staff for new divisions".

The company has strong product pipeline for the current financial year and more than 30 products are in the different stages of completion. "We have plans to launch 10 new products every quarter for various therapeutic segments. We are developing products for the gynaecology, orthopaedics, injectables, nutraceutical and surgery products at our R&D centre," Undwar further added.

TLPL's tablet, capsules and liquids manufacturing facility is located at Baddi in Himachal Pradesh. The company will be investing Rs 3-4 crore for the installation of latest equipments. It is also planning to enhance its tablet manufacturing capacity. With completion of expansion, the manpower strength will go up from present 80 to 100.

The company has its presence in more than 45 countries including CIS, South East Asia, West Indies and South America. It has filed applications for the Latin American markets and expecting to enter by the end of December 2008 with the existing product portfolio.

During the financial year 2007-08 its turnover reached up to Rs 300 crore as against Rs 200 crore in 2006-07. In the last fiscal company has generated Rs 40 crore sales from its Baddi unit and same is likely to reach up to Rs 60 crore in the current fiscal. Overall, it is targeting to generate a turnover of Rs 400 crore in 2008-09

"We are in the finalisation stage with Russia based Arc Life Sciences for marketing tie up. We are also exploring possibilities to tie-up with US based Herbal Life. These marketing agreements will be for whole Asia and likely to final shape by mid of July 2008".